Issue navigation
Volume 112, Issue 11, November 2020
Editorial
The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1079–1080, https://doi.org/10.1093/jnci/djaa029
Commentary
Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1081–1088, https://doi.org/10.1093/jnci/djaa041
Review
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1089–1097, https://doi.org/10.1093/jnci/djaa071
Articles
Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1098–1104, https://doi.org/10.1093/jnci/djaa032
International Trends in the Incidence of Cancer Among Adolescents and Young Adults
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1105–1117, https://doi.org/10.1093/jnci/djaa007
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma—An Institutional and National Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1118–1127, https://doi.org/10.1093/jnci/djaa002
Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1127–1136, https://doi.org/10.1093/jnci/djaa020
Disparities of National Lung Cancer Screening Guidelines in the US Population
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1136–1142, https://doi.org/10.1093/jnci/djaa013
Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1143–1152, https://doi.org/10.1093/jnci/djaa016
Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1153–1161, https://doi.org/10.1093/jnci/djaa022
Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1162–1169, https://doi.org/10.1093/jnci/djaa004
Brief Communication
Young-Onset Colon Cancer and Recurrence Risk by Gene Expression
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Pages 1170–1173, https://doi.org/10.1093/jnci/djaa019
Correspondence
RE: Breast Cancer Mortality After Implementation of Organized Population-Based Screening in Norway
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Page 1174, https://doi.org/10.1093/jnci/djaa129
Response to Zahl
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 11, November 2020, Page 1175, https://doi.org/10.1093/jnci/djaa130
